United Therap patents expiration
1. Orenitram patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6765117 | UNITED THERAP | Process for stereoselective synthesis of prostacyclin derivatives |
Oct, 2017
(6 years ago) | |
| US9050311 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(28 days from now) | |
| US7417070 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
Jul, 2026
(2 years from now) | |
| US11723887 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| US8497393 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| US9593066 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in remodulin® |
Dec, 2028
(4 years from now) | |
| US9604901 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5153222 | UNITED THERAP | Method of treating pulmonary hypertension with benzidine prostaglandins |
Oct, 2014
(9 years ago) | |
| US9422223 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(28 days from now) | |
| US9278901 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(28 days from now) | |
| US8252839 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(28 days from now) | |
| US7544713 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
Jul, 2024
(2 months from now) | |
| US9393203 | UNITED THERAP | Osmotic drug delivery system |
Apr, 2026
(2 years from now) | |
| US8410169 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
Feb, 2030
(5 years from now) | |
| US8349892 | UNITED THERAP | Solid formulations of prostacyclin analogs |
Jan, 2031
(6 years from now) | |
| US8747897 | UNITED THERAP | Osmotic drug delivery system |
Aug, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-272) | Oct 18, 2026 |
| New Dosage Form(NDF) | Dec 20, 2016 |
| New Indication(I-820) | Oct 18, 2022 |
| New Dosing Schedule(D-156) | Jan 28, 2019 |
| New Dosing Schedule(D-157) | Jan 28, 2019 |
| Orphan Drug Exclusivity(ODE-308) | Dec 20, 2020 |
Drugs and Companies using TREPROSTINIL DIOLAMINE ingredient
Market Authorisation Date: 20 December, 2013
Treatment: Use of orenitram for the treatment of pulmonary arterial hypertension (pah) (who group 1).; Method of treating pulmonary hypertension by orally administering a formulation of a pharmaceutically accept...
Dosage: TABLET, EXTENDED RELEASE;ORAL
ORENITRAM family patents
2. Remodulin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6765117 | UNITED THERAP | Process for stereoselective synthesis of prostacyclin derivatives |
Oct, 2017
(6 years ago) | |
| US11723887 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| US9604901 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| US8497393 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| US9593066 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in remodulin® |
Dec, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5153222 | UNITED THERAP | Method of treating pulmonary hypertension with benzidine prostaglandins |
Oct, 2014
(9 years ago) | |
| US9199908 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(28 days from now) | |
| US9713599 | UNITED THERAP | Parenteral formulations of treprostinil |
Dec, 2024
(7 months from now) | |
| US10076505 | UNITED THERAP | Inhalation formulations of Treprostinil |
Dec, 2024
(7 months from now) | |
| US10695308 | UNITED THERAP | Inhalation formulations of treprostinil |
Dec, 2024
(7 months from now) | |
| US8653137 | UNITED THERAP | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
Sep, 2028
(4 years from now) | |
| US8658694 | UNITED THERAP | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
Sep, 2028
(4 years from now) | |
| US7999007 | UNITED THERAP | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
Mar, 2029
(4 years from now) | |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 28 September, 2023
Treatment: Treatment of pulmonary hypertension with ut-15; Administration of remodulin diluted for intravenous infusion with sterile water for injection or 0.9% sodium chloride injection prior to administration...
Dosage: INJECTABLE;IV (INFUSION), SUBCUTANEOUS; SOLUTION;INTRAVENOUS, SUBCUTANEOUS
REMODULIN family patents
3. Tyvaso patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6765117 | UNITED THERAP | Process for stereoselective synthesis of prostacyclin derivatives |
Oct, 2017
(6 years ago) | |
| US9604901 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| US8497393 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| US11723887 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| US9593066 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in remodulin® |
Dec, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5153222 | UNITED THERAP | Method of treating pulmonary hypertension with benzidine prostaglandins |
Oct, 2014
(9 years ago) | |
| US6521212 | UNITED THERAP | Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation |
Nov, 2018
(5 years ago) | |
| US6756033 | UNITED THERAP | Method for delivering benzindene prostaglandins by inhalation |
Nov, 2018
(5 years ago) | |
| US10376525 | UNITED THERAP | Treprostinil administration by inhalation |
May, 2027
(3 years from now) | |
| US10716793 | UNITED THERAP | Treprostinil administration by inhalation |
May, 2027
(3 years from now) | |
| US9339507 | UNITED THERAP | Treprostinil administration by inhalation |
Mar, 2028
(3 years from now) | |
| US9358240 | UNITED THERAP | Treprostinil administration by inhalation |
May, 2028
(4 years from now) | |
| US11826327 | UNITED THERAP | Treatment for interstitial lung disease |
Jan, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-856) | Mar 31, 2024 |
| M(M-145) | May 20, 2017 |
| Orphan Drug Exclusivity(ODE) | Jul 30, 2016 |
| New Dosage Form(NDF) | Jul 30, 2012 |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 30 July, 2009
Treatment: Treatment of pulmonary hypertension; Treatment of pulmonary hypertension by inhalation; Method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a ...
Dosage: SOLUTION;INHALATION
TYVASO family patents
4. Tyvaso Dpi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9604901 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| US9593066 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in remodulin® |
Dec, 2028
(4 years from now) | |
| US11723887 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10130685 | UNITED THERAP | Diketopiperazine salts for drug delivery and related methods |
Aug, 2025
(1 year, 3 months from now) | |
| US10716793 | UNITED THERAP | Treprostinil administration by inhalation |
May, 2027
(3 years from now) | |
| US10772883 | UNITED THERAP | Diketopiperazine microparticles with defined specific surface areas |
Jun, 2030
(6 years from now) | |
| US10421729 | UNITED THERAP | Microcrystalline diketopiperazine compositions and methods |
Apr, 2035
(10 years from now) | |
| US11826327 | UNITED THERAP | Treatment for interstitial lung disease |
Jan, 2042
(17 years from now) | |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 23 May, 2022
Treatment: Method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device; Method of treating pulmonary hypertension associated with interstitial lung dise...
Dosage: POWDER;INHALATION
TYVASO DPI family patents